基本情報
- CAS
630-93-3- 標準SMILES
O=C1[N-]C(=O)C(c2ccccc2)(c2ccccc2)N1.[Na+]- InChIKey
FJPYVLNWWICYDW-UHFFFAOYSA-M- 分子式
- C15H11N2NaO2
- 平均分子量
- 274.25 g/mol
- 単同位体質量
- 274.07182188
概要
Diphenylhydantoin (Phenytoin), Sodium Salt can cause cancer according to an independent committee of scientific and health experts.
名称と識別子
- 優先名称
- Phenytoin Sodium
- IUPAC
- sodium 5,5-diphenylimidazolidin-3-ide-2,4-dione
- 現地名
- 5,5-ジフェニルヒダントインナトリウム
- 英語名
- Phenytoin sodium
- 分子式
- C15H13N2NaO2
- 分子量
- 276.27
名称と別名
PHENYTOIN SODIUM630-93-35,5-Diphenylhydantoin sodium saltDiphenylhydantoin SodiumTacosalAntisacerPhenytoin sodium saltDiphenylan sodiumPHENYTEKPrompt Phenytoin SodiumPhenytexDTXSID2023775
名称をさらに表示
5,5-ジフェニルヒダントインナトリウムエパヌチン5,5-ジフェニルヒダントインナトリウム塩エピランDフェニトインナトリウムジフェニンフェニトイン酸ナトリウム5,5-ジフェニルイミダゾリジン-2,4-ジオン·ナトリウムジランチンジフヒダンソランチル注射用フェニトインナトリウム5,5-ジフェニルヒダントイン ナトリウム塩フェニトインナトリウム (JP17)DILANTINSODIUM DIPHENYLHYDANTOINdi-lenditoinepelinepinateptoinenkefalalepsin
Extended Phenytoin SodiumPHENYTOIN SODIUM, PROMPTPhenytoin sodium,promptPhenytoin sodium extendedPhenytoin sodium,extended4182431BJH2,4-Imidazolidinedione, 5,5-diphenyl-, monosodium saltDTXCID803775
物性
構造計算による物性
- 極性表面積
- 47.2 Ų
- 水素結合供与体数
- 1
- 水素結合受容体数
- 3
- 回転可能結合数
- 2
- 重原子数
- 20
- 形式電荷
- 0
- 複雑度
- 356
実験および物理化学的性質
Human Drugs
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Animal DrugsFDA approved animal drugs -> Active ingredient
Collision Cross Section158.4 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
物理化学的性質
- 貯蔵温度
- Inert atmosphere,Room Temperature
- 溶解性
- 水性塩基: 可溶
- 外見
- 結晶性粉末
- 色
- 白～ほぼ白
- Merck
- 14 · 14,7322
- BCS Class
- 2 · 2
- 安定性
- Hygroscopic
- InChI
- InChI=1S/C15H12N2O2.Na.H/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12;;/h1-10H,(H2,16,17,18,19);;
- InChIKey
- FJPYVLNWWICYDW-UHFFFAOYSA-M
- SMILES
- O=C1NC(=O)NC1(C1C=CC=CC=1)C1C=CC=CC=1.[NaH]
- CAS データベース
- 630 · 630-93-3(CAS DataBase Reference)
- EPAの化学物質情報
- Diphenylhydantoin sodium (630-93-3)
安全と法規制
安全情報は参考情報です。供給元の安全データシート（SDS）、適用法令、専門家による評価に代わるものではありません。
GHS分類
GHS Classification
Danger
H301 (18.6%): Toxic if swallowed [Danger Acute toxicity, oral]
P203, P260, P261, P264, P270, P272, P280, P301+P316, P301+P317, P302+P352, P318, P319, P321, P330, P333+P317, P362+P364, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 194 reports by companies from 11 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
危険有害性情報
Regulatory Information
Hazard Traits - Carcinogenicity
REACH registered substance: Phenytoin sodium (EC: 211-148-2)
Phenytoin sodium: Does not have an individual approval but may be used under an appropriate group standard
Other Safety InformationIMAP assessments - 2,4-Imidazolidinedione, 5,5-diphenyl-, monosodium salt: Human health tier I assessment
Hazard Classes and CategoriesAcute Tox. 3 (18.6%)
毒性情報
Treatment
Treatment is nonspecific since there is no known antidote. The adequacy of the respiratory and circulatory systems should be carefully observed and appropriate supportive measures employed. Hemodialysis can be considered since phenytoin is not completely bound to plasma proteins. Total exchange transfusion has been used in the treatment of severe intoxication in pediatric patients. (L1712)
Health EffectsMay cause a potentially dangerous rash that may develop into Stevens Johnson syndrome, an extremely rare but potentially fatal skin disease.
Exposure Routes
化学と産業
薬理情報
Metabolism/Metabolites
Primarily hepatic. The majority of the dose (up to 90%) is metabolized to 5-(4'-hydroxyphenyl)-5-phenylhydantoin (p-HPPH). This metabolite undergoes further glucuronidation and is excreted into the urine. CYP2C19 and CYP2C9 catalyze the aforementioned reaction. Route of Elimination: Most of the drug is excreted in the bile as inactive metabolites which are then reabsorbed from the intestinal tract and excreted in the urine. Urinary excretion of phenytoin and its metabolites occurs partly with glomerular filtration but, more importantly, by tubular secretion. Half Life: 22 hours (range of 7 to 42 hours)
FDA Pharmacological Classification
EXTENDED PHENYTOIN SODIUM
Cytochrome P450 2C9 Inducers [MoA]; Decreased Central Nervous System Disorganized Electrical Activity [PE]; Anti-epileptic Agent [EPC]; Cytochrome P450 2B6 Inducers [MoA]; Cytochrome P450 3A Inducers [MoA]; Cytochrome P450 2C8 Inducers [MoA]; Cytochrome P450 1A2 Inducers [MoA]; Cytochrome P450 2C19 Inducers [MoA]; Cytochrome P450 2D6 Inducers [MoA]
PHENYTOIN SODIUM
Cytochrome P450 2D6 Inducers [MoA]; Cytochrome P450 1A2 Inducers [MoA]; Cytochrome P450 2C19 Inducers [MoA]; Cytochrome P450 2C8 Inducers [MoA]; Cytochrome P450 2B6 Inducers [MoA]; Cytochrome P450 3A Inducers [MoA]; Anti-epileptic Agent [EPC]; Decreased Central Nervous System Disorganized Electrical Activity [PE]; Cytochrome P450 2C9 Inducers [MoA]
MeSH Pharmacological Classification
Drugs used to prevent SEIZURES or reduce their severity.
A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS.
Drugs and compounds that induce the synthesis of CYTOCHROME P-450 CYP1A2.
用途と製造
UsesFor the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery.
General Manufacturing Information
関連反応
2 件
化合物ノート
読み込み中…